1-(chloromethoxy)butane

We are 1-(chloromethoxy)butane CAS:2351-69-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 2351-69-1
Product Name: 1-(chloromethoxy)butane
Other Name:
1-(chloromethoxy)butane
Butoxymethylchloride
Butyl-chloromethyl ether
Chloromethyl n-butyl ether
Butoxychloromethane
 
Density: 0.951
Boiling Point: 121ºC
Molecular Formula: C5H11ClO
Molecular Weight: 122.59300
Flash Point: 39ºC
Exact Mass: 122.05000
PSA: 9.23000
LogP: 1.99940
Index of Refraction: 1.4141-1.4208
 
Specification
Appearance: Colorless to light yellow transparent liquid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Butachlor CAS: 23184-66-9.
Be used as pesticide intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

1-(chloromethoxy)butane


Related News: APIs are generally manufactured through a variety of processes that include.[2 – [(2-amino-6-oxo-3H-purin-9-il) metoxi] -3-hidroxipropil] acetato CAS:88110-89-8 Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.111-31-9 In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.arsorosomethane In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
Trifluoroacetic anhydride View Details
4-isothiocyanatobenzonitrile View Details
1-Benzyl-4-(phenylamino)piperidine-4-carbonitrile View Details
3-Bromo-2-hydroxypyridine manufacturer 5-Fluoroindole-2-carboxylic acid manufacturer 3-bromo-5-methylpyridine manufacturer 2-Methyl-4-nitrobenzoic acid manufacturer Acetyl Octapeptide-3 manufacturer